RBC Capital analyst Sean Dodge maintained a Buy rating on Catalent (NYSE:CTLT) on Monday, setting a price target of $125, which is approximately 8.93% above the present share price of $114.75.
Dodge expects Catalent to post earnings per share (EPS) of $0.42 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Catalent, with an average price target of $116.13.
The analysts price targets range from a high of $130 to a low of $100.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $845.7 million and a net profit of $84.2 million. The company's market cap is $18.9 billion.
According to TipRanks.com, RBC Capital analyst Sean Dodge is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.4% and a 63.24% success rate.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.